Inge M. van der Sluis

5.4k citations

104 papers · 3.2k indexed · 1 hit paper · h-index 29

Public Health, Environmental and Occupational Health top 1%
Pediatrics, Perinatology and Child Health top 0.5%
Orthopedics and Sports Medicine top 1%
Oncology top 5%
Hematology top 2%

Co-authors: Sabine M.P.F. de Muinck Keizer‐Schrama Rob Pieters Eric P. Krenning Marry M. van den Heuvel‐Eibrink Annemieke M. Boot Nobuko Hijiya Wim C.J. Hop Gertjan J.L. Kaspers
Topics: Acute Lymphoblastic Leukemia research (59 papers)Childhood Cancer Survivors' Quality of Life (53 papers)Adolescent and Pediatric Healthcare (17 papers)
Cited by: Pediatrics, Perinatology and Child Health Orthopedics and Sports Medicine Public Health, Environmental and Occupational Health
Journals: New England Journal of Medicine Journal of Clinical OncologySHILAP Revista de lepidopterología
Partner nations: Netherlands United States Germany

In The Last Decade

Inge M. van der Sluis

99 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

2023 83 citations Inge M. van der Sluis, Rob Pieters et al. profile →

Peers

Countries citing papers authored by Inge M. van der Sluis

Since Specialization

Citations

This map shows the geographic impact of Inge M. van der Sluis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge M. van der Sluis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge M. van der Sluis more than expected).

Fields of papers citing papers by Inge M. van der Sluis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge M. van der Sluis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge M. van der Sluis. The network helps show where Inge M. van der Sluis may publish in the future.

Co-authorship network of co-authors of Inge M. van der Sluis

This figure shows the co-authorship network connecting the top 25 collaborators of Inge M. van der Sluis. A scholar is included among the top collaborators of Inge M. van der Sluis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge M. van der Sluis. Inge M. van der Sluis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Therapeutic drug monitoring in acute lymphoblastic leukemia–a deep dive into pharmacokinetics, -dynamics, and -genetics of antileukemic drugs 2025 ·Expert Review of Clinical Pharmacology ·(unknown),(unknown),Inge M. van der Sluis,Erica Brivio,Raheel Altaf Raja,(unknown),(unknown),(unknown),(unknown),Katrine Kielsen,Bodil Als‐Nielsen,Sarah Elitzur,Kim Dalhoff,Kjeld Schmiegelow,Cecilie Utke Rank	1
2	Therapeutic drug monitoring in the treatment of childhood acute lymphoblastic leukemia – A practical guideline 2025 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),Jesper Heldrup,(unknown),Marianne Ifversen,Stine Nygaard Nielsen,Kjeld Schmiegelow,Inge M. van der Sluis	1
3	Health-related quality of life and its determinants during and after treatment for paediatric acute lymphoblastic leukaemia: a national, prospective, longitudinal study in the Netherlands 2023 ·BMJ Open ·(unknown),(unknown),Lindsay M. H. Steur,Reinoud J. B. J. Gemke,Natasha K. A. van Eijkelenburg,Inge M. van der Sluis,Natasja Dors,Cor van den Bos,Wim J. E. Tissing,Martha A. Grootenhuis,Gertjan J.L. Kaspers,Raphaële R. L. van Litsenburg	4
4	Higher incidence of delayed methotrexate clearance in pediatric acute lymphoblastic leukemia patients treated with imatinib 2023 ·SHILAP Revista de lepidopterología ·Inge M. van der Sluis,(unknown),(unknown),(unknown),Rob Pieters	1
5	Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy 2022 ·SHILAP Revista de lepidopterología ·(unknown),(unknown),(unknown),(unknown),Wim J. E. Tissing,Rob Pieters,Inge M. van der Sluis,(unknown)	1
6	Experience with ponatinib in paediatric patients with leukaemia 2020 ·British Journal of Haematology ·Jenna Rossoff,Van Huynh,Rachel E. Rau,Margaret E. Macy,Maria Luisa Sulis,Kirk R. Schultz,Michael J. Burke,Uma H. Athale,Maureen M. O’Brien,John Gregory,Inge M. van der Sluis,Frank G. Keller,C. Michel Zwaan,Meinolf Suttorp,Nobuko Hijiya	20
7	High prevalence of parent‐reported sleep problems in pediatric patients with acute lymphoblastic leukemia after induction therapy 2020 ·Pediatric Blood & Cancer ·Lindsay M. H. Steur,Martha A. Grootenhuis,Eus J.W. Van Someren,Natasha K. A. van Eijkelenburg,Inge M. van der Sluis,Natasja Dors,Cor van den Bos,Wim J. E. Tissing,Gertjan J.L. Kaspers,Raphaële R. L. van Litsenburg	26
8	Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion 2020 ·ESMO Open ·André Baruchel,Patrick A. Brown,Carmelo Rizzari,Lewis B. Silverman,Inge M. van der Sluis,Benjamin Ole Wolthers,Kjeld Schmiegelow	23
9	Pharmacokinetics and population pharmacokinetics in pediatric oncology 2019 ·Pediatric Blood & Cancer ·(unknown),C. Michel Zwaan,Inge M. van der Sluis,Ron A. A. Mathôt	6
10	Sleep–wake rhythm disruption is associated with cancer-related fatigue in pediatric acute lymphoblastic leukemia 2019 ·SLEEP ·Lindsay M. H. Steur,Gertjan J.L. Kaspers,Eus J.W. Van Someren,Natasha K. A. van Eijkelenburg,Inge M. van der Sluis,Natasja Dors,Cor van den Bos,Wim J. E. Tissing,Martha A. Grootenhuis,Raphaële R. L. van Litsenburg	26
11	Population Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Prophylaxis in Pediatric Acute Lymphoblastic Leukemia Patients 2019 ·Clinical Infectious Diseases ·(unknown),Ron A. A. Mathôt,Rob Pieters,Válerie de Haas,Gertjan J.L. Kaspers,Cor van den Bos,Wim J. E. Tissing,D. Maroeska W. M. te Loo,Marc Bierings,Mireille van Westreenen,Inge M. van der Sluis,C. Michel Zwaan	5
12	Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis 2019 ·Research and Practice in Thrombosis and Haemostasis ·(unknown),Mandy N. Lauw,Marta Fiocco,Inge M. van der Sluis,Rob Pieters,(unknown),Marianne D. van de Wetering,Hester A. de Groot‐Kruseman,C. Heleen van Ommen	38
13	Drug-drug interactions in pediatric oncology patients 2017 ·Pediatric Blood & Cancer ·(unknown),(unknown),Teun van Gelder,(unknown),Inge M. van der Sluis,Roelof W. F. van Leeuwen,Frederike K. Engels	17
14	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients 2016 ·Haematologica ·(unknown),Ron A. A. Mathôt,Rob Pieters,(unknown),Válerie de Haas,Gertjan J.L. Kaspers,Cor van den Bos,Wim J. E. Tissing,D. Maroeska W. M. te Loo,Marc Bierings,Wouter J.W. Kollen,C. Michel Zwaan,Inge M. van der Sluis	16
15	Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia 2015 ·Haematologica ·(unknown),Saskia M.F. Pluijm,M.L. te Winkel,Hester A. de Groot‐Kruseman,Marta Fiocco,Peter M. Hoogerbrugge,J. A. Leeuw,Marrie C.A. Bruin,Inge M. van der Sluis,Dorine Bresters,Maarten H. Lequin,Jan C. Roos,A. Veerman,Rob Pieters,Marry M. van den Heuvel‐Eibrink	20
16	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia 2014 ·Blood ·Wing H. Tong,Rob Pieters,Gertjan J.L. Kaspers,D. Maroeska W. M. te Loo,Marc Bierings,Cor van den Bos,Wouter J.W. Kollen,Wim C.J. Hop,Claudia Lanvers‐Kaminsky,Mary V. Relling,Wim J. E. Tissing,Inge M. van der Sluis	155
17	Bone Mineral Density and Body Composition in Adolescents with Childhood-Onset Growth Hormone Deficiency 2009 ·Hormone Research in Paediatrics ·Annemieke M. Boot,Inge M. van der Sluis,Eric P. Krenning,Sabine M.P.F. de Muinck Keizer‐Schrama	36
18	Estrogen Receptor α Gene Polymorphisms and Bone Mineral Density in Healthy Children and Young Adults 2004 ·Calcified Tissue International ·Annemieke M. Boot,Inge M. van der Sluis,Sabine M.P.F. de Muinck Keizer‐Schrama,Joyce B. J. van Meurs,E. P. Krenning,Huibert A. P. Pols,André G. Uitterlinden	46
19	Reference data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults 2002 ·Archives of Disease in Childhood ·Inge M. van der Sluis	283
20	Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood 2000 ·Medical and Pediatric Oncology ·Inge M. van der Sluis,Marry M. van den Heuvel‐Eibrink,(unknown),Eric P. Krenning,Sabine M.P.F. de Muinck Keizer‐Schrama	99

About Inge M. van der Sluis

Inge M. van der Sluis is a scholar working on Pediatrics, Perinatology and Child Health, Speech and Hearing and Orthopedics and Sports Medicine, having authored 104 papers that have together received 3.2k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (59 papers), Childhood Cancer Survivors' Quality of Life (53 papers) and Adolescent and Pediatric Healthcare (17 papers). The work is most often cited by research in Pediatrics, Perinatology and Child Health (1.3k citations), Orthopedics and Sports Medicine (592 citations) and Public Health, Environmental and Occupational Health (1.4k citations). Inge M. van der Sluis has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Sabine M.P.F. de Muinck Keizer‐Schrama, Rob Pieters, Eric P. Krenning, Marry M. van den Heuvel‐Eibrink, Annemieke M. Boot, Nobuko Hijiya, Wim C.J. Hop, Gertjan J.L. Kaspers, Cor van den Bos and Wim J. E. Tissing. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact